Literature DB >> 17909062

Dynamics of the immune reaction to pancreatic cancer from inception to invasion.

Carolyn E Clark1, Sunil R Hingorani, Rosemarie Mick, Chelsea Combs, David A Tuveson, Robert H Vonderheide.   

Abstract

The dynamics of cancer immunosurveillance remain incompletely understood, hampering efforts to develop immunotherapy of cancer. We evaluated the evolving in vivo immune response to a spontaneous tumor in a genetically defined mouse model of pancreatic ductal adenocarcinoma from the inception of preinvasive disease to invasive cancer. We observed a prominent leukocytic infiltration even around the lowest grade preinvasive lesions, but immunosuppressive cells, including tumor-associated macrophages, myeloid-derived suppressor cells (MDSC), and regulatory T cells (Treg), dominated the early response and persisted through invasive cancer. Effector T cells, however, were scarce in preinvasive lesions, found in only a subset of advanced cancers, and showed no evidence of activation. The lack of tumor-infiltrating effector T cells strongly correlated with the presence of intratumoral MDSC with a near mutual exclusion. In vitro, we found that MDSC suppressed T-cell proliferation. Overall, our results show that suppressive cells of the host immune system appear early during pancreatic tumorigenesis, preceding and outweighing antitumor cellular immunity, and likely contribute to disease progression. Thus, in contrast to the hypothesis that an early "elimination phase" of cancer immunosurveillance is eventually overwhelmed by a growing invasive tumor, our findings suggest that productive tumor immunity may be undermined from the start. Efforts to test potent inhibitors of MDSC, tumor-associated macrophages, and Treg, particularly early in the disease represent important next steps for developing novel immunotherapy of cancer.

Entities:  

Mesh:

Year:  2007        PMID: 17909062     DOI: 10.1158/0008-5472.CAN-07-0175

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  411 in total

1.  Development of an orthotopic model of invasive pancreatic cancer in an immunocompetent murine host.

Authors:  William W Tseng; Daniel Winer; Justin A Kenkel; Okmi Choi; Alan H Shain; Jonathan R Pollack; Randy French; Andrew M Lowy; Edgar G Engleman
Journal:  Clin Cancer Res       Date:  2010-06-09       Impact factor: 12.531

Review 2.  Pancreatic ductal adenocarcinoma: a review of immunologic aspects.

Authors:  Megan B Wachsmann; Laurentiu M Pop; Ellen S Vitetta
Journal:  J Investig Med       Date:  2012-04       Impact factor: 2.895

Review 3.  Cdx genes, inflammation, and the pathogenesis of intestinal metaplasia.

Authors:  Douglas B Stairs; Jianping Kong; John P Lynch
Journal:  Prog Mol Biol Transl Sci       Date:  2010       Impact factor: 3.622

Review 4.  Re-adapting T cells for cancer therapy: from mouse models to clinical trials.

Authors:  Ingunn M Stromnes; Thomas M Schmitt; Aude G Chapuis; Sunil R Hingorani; Philip D Greenberg
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

5.  A CD40 Agonist and PD-1 Antagonist Antibody Reprogram the Microenvironment of Nonimmunogenic Tumors to Allow T-cell-Mediated Anticancer Activity.

Authors:  Hayley S Ma; Bibhav Poudel; Evanthia Roussos Torres; John-William Sidhom; Tara M Robinson; Brian Christmas; Blake Scott; Kayla Cruz; Skylar Woolman; Valerie Z Wall; Todd Armstrong; Elizabeth M Jaffee
Journal:  Cancer Immunol Res       Date:  2019-01-14       Impact factor: 11.151

Review 6.  Chimeric antigen receptor T cell therapy in pancreatic cancer: from research to practice.

Authors:  Vishal Jindal; Ena Arora; Muhammad Masab; Sorab Gupta
Journal:  Med Oncol       Date:  2018-05-04       Impact factor: 3.064

7.  Targeted depletion of an MDSC subset unmasks pancreatic ductal adenocarcinoma to adaptive immunity.

Authors:  Ingunn M Stromnes; J Scott Brockenbrough; Kamel Izeradjene; Markus A Carlson; Carlos Cuevas; Randi M Simmons; Philip D Greenberg; Sunil R Hingorani
Journal:  Gut       Date:  2014-02-20       Impact factor: 23.059

8.  Upregulated Expression of CUX1 Correlates with Poor Prognosis in Glioma Patients: a Bioinformatic Analysis.

Authors:  Xiujie Wu; Fan Feng; Chuanchao Yang; Moxuan Zhang; Yanhao Cheng; Yayun Zhao; Yayu Wang; Fengyuan Che; Jian Zhang; Xueyuan Heng
Journal:  J Mol Neurosci       Date:  2019-08-03       Impact factor: 3.444

Review 9.  Immune Therapy in GI Malignancies: A Review.

Authors:  Judy Wang; Kim A Reiss; Rina Khatri; Elizabeth Jaffee; Dan Laheru
Journal:  J Clin Oncol       Date:  2015-04-27       Impact factor: 44.544

10.  Interleukin-6 is required for pancreatic cancer progression by promoting MAPK signaling activation and oxidative stress resistance.

Authors:  Yaqing Zhang; Wei Yan; Meredith A Collins; Filip Bednar; Sabita Rakshit; Bruce R Zetter; Ben Z Stanger; Ivy Chung; Andrew D Rhim; Marina Pasca di Magliano
Journal:  Cancer Res       Date:  2013-10-04       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.